.jpg?format=webp&width=780)
Approximately one‐third of patients with type 2 diabetes (T2D) have cardiovascular disease (CVD). The 2019 ESC and ADA/EASD guidelines and updated (2021) ESC guidelines recommend glucagon‐like peptide‐1 (GLP‐1) receptor agonists (as first‐ or second‐line glucose‐lowering medication for these patients. The study investigated the budget implications of treatment with GLP‐1 receptor agonists versus other glucose‐lowering treatments between 2012 and 2019. Post‐index date, mean observed total costs were numerically lower for patients receiving a GLP‐1 receptor agonist compared with SoC ($3853 vs $4288). In adjusted analysis both groups had similar total healthcare costs (p = 0.56). These findings suggest that, in US patients with T2D and a CVD‐related hospitalization, the added medical costs of treatment with GLP‐1 receptor agonists is offset by lower inpatient and outpatient care costs, resulting in budget neutrality against SoC.
Like
Save
Share